India Remdesivir Black Market: Supply Gap May Normalize Soon, But No End To Greed

Gilead Licensees Moving To Improve Supplies

India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.

Drug remdesivir for covid 19 coronavirus treatment
Supplies of remdesivir build up in India • Source: Shutterstock

If the frantic messages from families of patients in India seeking supplies of generic versions of Gilead Sciences, Inc.’s investigational antiviral remdesivir - in the spotlight as a potential treatment for COVID-19 - are any reflection of the situation on the ground, then it’s not a very pretty scene.

And with instances of black marketing and other exploitative practices by alleged middlemen being reported, greed may be taking the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia